IgG4-related disease (IgG4-RD) is a chronic fibro-inflammatory disease that may cause dysfunction in various organs. World-wide multidisciplinary experts attending the Fourth International Symposium on IgG4-Related Disease in Japan in 2021… Click to show full abstract
IgG4-related disease (IgG4-RD) is a chronic fibro-inflammatory disease that may cause dysfunction in various organs. World-wide multidisciplinary experts attending the Fourth International Symposium on IgG4-Related Disease in Japan in 2021 discussed treatments for IgG4-RD, especially glucocorticoid (GC) therapy. This review describes the efficacy, safety, and cost of treatments for IgG4-RD based on findings presented at the international symposium. A medium dose of GC was considered appropriate for the initial treatment of IgG4-RD. A randomized controlled trial (RCT) and an open-label prospective study have shown that long-term maintenance GC therapy (prednisolone ≥ 5 mg/day) could prevent disease relapse. In addition, two open-label RCTs reported the effects of combinational use of GC and synthetic immunosuppressive agents, mycophenolate mofetil and leflunomide, on relapse prevention. Moreover, an open-label single-arm study showed an excellent rate of clinical response to rituximab. Many observational studies have shown the efficacy of an appropriate GC regimen in patients with IgG4-RD. Synthetic immunosuppressive agents and a molecular-targeted agent can be potent alternatives to GCs, but additional studies are required comparing their efficacy, risk of infection, and costs.
               
Click one of the above tabs to view related content.